# Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

> **NCT00903656** · PHASE2 · TERMINATED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** doxorubicinhydrochloride, Lapatinib

## Key facts

- **NCT ID:** NCT00903656
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Caelyx was not available anymore
- **Last updated:** 2013-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903656, "Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00903656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*